1 |
Muster R, Ko N, Smith W, Su H, Dickey MA, Nelson J, McCulloch CE, Sneed PK, Clarke JL, Saloner DA, Eisenmenger L, Kim H, Cooke DL. Proof-of-concept single-arm trial of bevacizumab therapy for brain arteriovenous malformation. BMJ Neurol Open 2021;3:e000114. [PMID: 34189463 DOI: 10.1136/bmjno-2020-000114] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
|
2 |
Shen F, Mao L, Zhu W, Lawton MT, Pechan P, Colosi P, Wu Z, Scaria A, Su H. Inhibition of pathological brain angiogenesis through systemic delivery of AAV vector expressing soluble FLT1. Gene Ther 2015;22:893-900. [PMID: 26090874 DOI: 10.1038/gt.2015.57] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
3 |
Nishimura T, Furihata M, Kubo H, Tani M, Agawa S, Setoyama R, Toyoda T. Intracranial hemorrhage in patients treated with bevacizumab: Report of two cases. World J Gastroenterol 2011; 17(39): 4440-4444 [PMID: 22110272 DOI: 10.3748/wjg.v17.i39.4440] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
4 |
Chen W, Choi EJ, McDougall CM, Su H. Brain arteriovenous malformation modeling, pathogenesis, and novel therapeutic targets. Transl Stroke Res 2014;5:316-29. [PMID: 24723256 DOI: 10.1007/s12975-014-0343-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
|
5 |
Ohta M. Causality assessment between reported fatal cerebral haemorrhage and suspected drugs: developing a new algorithm based on the analysis of the Japanese Adverse Event Report (JADER) database and literature review. Eur J Clin Pharmacol 2021;77:1443-52. [PMID: 33829295 DOI: 10.1007/s00228-021-03131-y] [Reference Citation Analysis]
|